$MANE

Investing.com reports Friday’s market weakness, with Nasdaq down about 1% and stocks set for a weekly loss. It lists major movers including Micron Tech (MU) up 3.66%, Oracle (ORCL) up 2.7%, and Coca-Cola (KO) down 4.66% after fairlife suspends US production following a cyberattack. Other cited moves include Applied Materials (AMAT) down 4.3% and SpaceX (SPCX) down 4.07%.

Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.

Veradermics (NYSE:MANE) reported positive Phase 2 results for VDPHL01 in women with female pattern hair loss. In a 6-month study at 4.5 mg once daily or twice daily, hair count increased about 22.7 and 23.3 hairs/cm², respectively. By month six, 88.9% and 90% reported improved coverage, with no treatment-related serious adverse events. Shares were up 15.01% to $126.71.

Veradermics (NYSE: MANE) said its extended-release oral minoxidil tablet VDPHL01 showed clinically meaningful hair growth in women with female pattern hair loss in Phase 2 Study 207. In 22 women over 6 months, once-daily and twice-daily doses increased non-vellus hair counts by 22.7 and 23.3 hairs/cm², with no treatment-related serious adverse events. Enrollment for Study 306 continues; topline expected H1 2027.

U.S. stocks rose on Wednesday, with the Dow up about 100 points. Reuters reported a bid proposal of $60.50 per share, supported by nearly $50 billion in committed bank financing, implying a 28% premium to PayPal’s Tuesday close. PayPal shares rose 13.5% to $53.74. Other big stocks also gained.

Veradermics (NYSE:MANE) shares rose about 9% after the company reported positive Phase 2 results for VDPHL01, its oral treatment for female pattern hair loss. Study 207 showed 88.9% (once daily) and 90.0% (twice daily) had improved outcomes at Month 6, with no treatment-related serious cardiac events reported through then. Topline results for Study 306 are expected in H1 2027.

Veradermics, Incorporated (NYSE: MANE) announced the pricing of an upsized public offering of 3,843,790 shares of its common stock at $100.00 per share, expecting to generate approximately $384.4 million in gross proceeds. Concurrently, the company is conducting a private placement of 300,000 pre-funded warrants to affiliates of Suvretta Capital, anticipating around $30.0 million in gross proceeds. Both offerings are expected to close on May 1, 2026, and the funds will support the clinical-stage biopharmaceutical company focused on developing therapeutics for pattern hair loss.

Veradermics' stock surged over 47% after its oral minoxidil drug, VDPHL01, showed significant improvements in a pivotal Phase II/III trial for male pattern baldness. The treatment demonstrated superior hair growth and patient-reported benefits compared to placebo and was well-tolerated. If approved, VDPHL01 could be the first non-hormonal pill for pattern hair loss to receive FDA clearance in nearly three decades, potentially tapping into a $2 billion or more market opportunity.

Veradermics (NYSE: MANE) is a late clinical-stage biopharmaceutical company focusing on developing VDPHL01, an extended-release oral minoxidil for treating pattern hair loss (PHL) in both men and women. The company is conducting three registration-directed, placebo-controlled trials for VDPHL01. Veradermics estimates the U.S. PHL treatment market at approximately $9 billion annually and plans a cash-pay, multi-channel commercial strategy, leveraging its patent protection expected to extend into at least 2043.